CJC-1295 has one of the strongest published human clinical records of any wellness-market peptide, a Phase 2 trial that was discontinued after a participant death, and a December 2024 FDA advisory committee vote against allowing it into the regulated compounding system. The gap between the science and the regulatory verdict is where its current safety story sits.

The compound has been on the wellness market for almost twenty years. It is one of a small number of peptides for which a properly designed human clinical trial exists. It is also one that the company that developed it stopped developing, that the FDA spent three years classifying as a substance of significant safety concern, and that the agency’s advisory committee, given a chance to admit it into the regulated compounding system, voted against. Athletes subject to drug testing cannot use it. The wellness clinics that prescribe it operate in a regulatory grey zone the FDA has been narrowing for the past two years.

That is the regulatory backdrop. The clinical backdrop is what follows.

What CJC-1295 actually is

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, the natural signal the hypothalamus sends to the pituitary gland to tell it to release growth hormone. Native GHRH has a plasma half-life of roughly two minutes, long enough to trigger a pulse of growth hormone release, then gone. CJC-1295 is engineered to do the same job while staying active in the bloodstream for far longer.

The compound was developed by ConjuChem Biotechnologies in the early 2000s. It comes in two forms. The version with a Drug Affinity Complex (DAC) binds to albumin in the blood and stays active for six to eight days, which is what allows weekly rather than daily injection. The version without DAC, often referred to as Modified GRF (1-29) or Mod GRF, has a half-life closer to thirty minutes and produces a more pulsatile pattern of growth hormone release that more closely resembles the body’s own.

Both versions work upstream of growth hormone itself. They do not introduce growth hormone into the body the way exogenous human growth hormone administration does. They signal the pituitary to release more of its own, within whatever limits the pituitary still has the capacity to produce.

The wellness use case is built on what growth hormone is associated with in healthy biology: tissue repair, fat metabolism, sleep architecture, lean mass retention. The clinical reality is more complicated. Whether stimulating the pituitary to release more growth hormone translates to those outcomes in adults whose endocrine systems are already functioning is a question the original clinical programme was designed to answer and the wellness market has not waited for an answer to.

What the Teichman 2006 trial actually showed

The canonical human trial for CJC-1295 was published in March 2006 in The Journal of Clinical Endocrinology & Metabolism by Sam Teichman and colleagues, including Lawrence Frohman, the endocrinologist whose lab at the University of Illinois had been working on growth hormone biology for decades. The study was a randomised, double-blind, placebo-controlled examination of CJC-1295 with DAC in healthy adults aged 21 to 64.

A single subcutaneous injection produced mean increases in growth hormone of two- to ten-fold above baseline, and increases in insulin-like growth factor 1 (IGF-1) of 1.5- to threefold. Both elevations were sustained for up to six days. A companion study in the same journal by Madalina Ionescu and Frohman established that the natural pulsatile pattern of growth hormone secretion was preserved during continuous CJC-1295 stimulation rather than flattened.

Side effects in the Teichman trial were described as mild and transient: injection-site irritation, headache, vasodilation (flushing), and occasional gastrointestinal upset. No serious adverse events occurred during the trial period reported in the published paper.

What the trial did not measure is the question the wellness market answers with marketing copy. The endpoints were pharmacokinetic and pharmacodynamic (what the peptide did to GH and IGF-1 levels), not clinical. Body composition was not a primary outcome. Sleep was not measured. Recovery from exercise was not assessed. Whether the documented hormonal elevation translated to the outcomes that CJC-1295 is now sold for is not what the 2006 trial was designed to answer.

Dr Dan Reardon, a UK A&E physician who works with athletes and treats peptide-related cases in emergency departments, explains the broader pharmacological logic of why this matters.

“A lot of the more common peptides on the market […] affect growth hormone release [and] they act as analogs,” Reardon says. “So theoretically it’s that jolt in growth hormone. [But an] elevated growth hormone doesn’t necessarily do anything. […] If you’re just boosting growth hormone, but you’re not necessarily getting any measurable outcome in terms of improved muscle strength, improved recovery, reduced joint inflammation, reduced joint pain, improved mobility, flexibility, all of those sorts of things […] there’s no benefit to actually taking it in the first place.”

The principle applies directly to CJC-1295. The trial established that the peptide elevates the hormones it was designed to elevate. The question of what that elevation produces in lived outcomes is the gap.

What clinicians who prescribe it actually see

The wellness clinics that prescribe CJC-1295 work from clinical experience rather than from outcome trials. Dr Neil Paulvin, a functional medicine practitioner who has prescribed it widely, describes a variable picture.

“CJC-1295 is a growth hormone receptor agonist,” Paulvin says. “It helps make growth hormone more effective. It may raise growth hormone levels, though I’ve had patients say their growth hormone didn’t increase, but it was still making it work better. We use CJC-1295 specifically for sleep, skin, recovery, and muscle-building, since it works through the growth hormone pathway.”

Paulvin’s honest summary of the clinical picture is that response is inconsistent.

“With CJC-1295, it’s really a mix,” he says. “Some people say their workouts are better. Some say their sleep improves. Some notice better skin. So the feedback is often anecdotal. We don’t automatically monitor growth hormone levels. […] I’ve had patients where their IGF or other growth hormone markers don’t move — and others where they increase. It goes back to this; how empty is the person’s tank? If their tank is full, you might not see a change in the labs, but you might still get a noticeable response in terms of how they feel.”

Dr Adrijana Kekic, a Doctor of Pharmacy and faculty member at the Geneva College of Longevity Sciences who lectures on peptide compounding practice, gives a similar account of CJC-1295 specifically.

“[CJC-1295 is] going to be very similar to BPC-157,” Kekic says. “We still need evidence about it. […] I see some really good results with specific people, but almost nothing with others. So it really depends.”

Both clinicians describe the same pattern: a compound that produces dramatic results in some users and nothing measurable in others, with no reliable way to predict which group a given person will fall into in advance. The wellness market sells the dramatic-results pattern. The clinical practice acknowledges both.

The safety picture: what the record contains

The reported short-term side-effect profile of CJC-1295 in healthy adults is mild and aligns broadly with what the Teichman trial documented: flushing, headache, injection-site irritation, occasional diarrhoea. These are typical of elevated growth hormone exposure and tend to be dose-dependent. Most consumer reports of CJC-1295 side effects describe the same cluster.

The more serious safety questions are three.

The first is what happened to the original ConjuChem programme. CJC-1295 reached Phase 2 clinical trials before commercial development was halted following the death of a trial participant. The attending physician, according to the published record summarised in the encyclopaedic literature on the compound, believed the most likely explanation was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and concluded that the event was unrelated to treatment with CJC-1295. ConjuChem nonetheless ended the development programme. The trial was the last formal Phase 2 work on the compound. The two-decade wellness-market history of CJC-1295 since then has been built on the Teichman pharmacokinetic data and on accumulated clinical-practice observation, not on completed late-stage trials.

The second is the angiogenesis and IGF-1 question. Growth hormone and IGF-1 are involved in cellular growth and repair across most tissue types, which is the basis for their wellness-market appeal. They are also signals that influence the growth of cells that should not be growing. The Vasireddi review of BPC-157 published in HSS Journal in July 2025 names the concern explicitly for that compound; the logic applies more directly to CJC-1295, because CJC-1295’s whole purpose is to elevate GH and IGF-1 levels.

Reardon describes the broader category-level concern.

“[Super physiological levels of growth hormone have] never been proven to be of any benefit,” Reardon says. “In fact, there might even be potential risks to that. Tumors growing faster. Potentially […] sometimes when it’s combined with other […] typical drugs that bodybuilders might use, you start to get an increase in the size of the bowel and bowel thickness and […] other problems that can be associated with that.”

Kekic, asked specifically about CJC-1295, is unambiguous about who should not take it.

“[W]hat I would probably use caution with [in the] majority of peptides, including [CJC-1295] as well, is going to be if you have an active cancer, you are not a good candidate for these,” she says. “If you have a predisposition and you are under a lot of stress where those cancer cells really can start to grow, especially if you’re using […] high protein diet that is really high amounts of methionine amino acid […] I would be very cautious.”

Paulvin’s clinical practice operates within the same caution.

“There is a theoretical risk,” Paulvin says. “So we don’t use it continuously — only for a couple of months at a time. And if anyone has a history of active cancer, we don’t use it at all.”

Three independent clinicians, in different practices, with different orientations to the peptide market, naming the same contraindication. People with active cancer, recent cancer history, or known cancer predispositions are not candidates for CJC-1295. This is the single safety message that the wellness-clinic marketing of the compound consistently understates.

The third safety question is the supply chain. Because CJC-1295 is not approved as a medicine in any major jurisdiction, the product that consumers actually take is produced by chemical synthesis companies operating outside pharmaceutical regulation.

“When it comes to safety, I am of the belief that anything that we give to somebody, there should be the right levels of safety,” Reardon says. “We should know where the product’s coming from, how it’s been manufactured, how it’s been imported, just some of the basic stuff. And the thing with peptides is compounding facilities are getting closed around the world left, right and centre. So we don’t have that same sort of rigour, if you like, on just overall safety.”

The regulatory verdict

The legal and regulatory position differs by jurisdiction, and the position is currently in motion.

• United States. CJC-1295 is not FDA-approved for any indication. In September 2023, the FDA placed it in Category 2 of its interim 503A bulks list: substances flagged for significant safety concerns that compounding pharmacies could not legally produce. In September 2024, the FDA removed CJC-1295 from Category 2 after the original nominators withdrew their submissions, and referred the compound to the Pharmacy Compounding Advisory Committee (PCAC) for formal review. At the December 4, 2024 PCAC meeting, the committee voted against including CJC-1295 in the 503A bulks regulation. The decision did not have the force of final FDA action (that requires a Federal Register notice that has not yet been published), but it is the most recent considered view of the FDA’s advisory body. Compounding pharmacies preparing CJC-1295 for patients with prescriptions are doing so within a regulatory environment the FDA has signalled it does not currently intend to formalise.
• United Kingdom. CJC-1295 is an unlicensed medicine. The Medicines and Healthcare products Regulatory Agency has not approved it for any clinical indication. It cannot lawfully be marketed for human consumption, sold as a supplement, or prescribed on the NHS. It can be sold as a research chemical labelled “for research purposes only / not for human consumption.” This is a legal grey area rather than a clear permission.
• Athletes. The World Anti-Doping Agency lists CJC-1295 on its Prohibited List under category S2.2.4 (Growth Hormone Releasing Factors). The category includes growth-hormone-releasing hormone analogues and their secretagogues. It is prohibited at all times, in and out of competition. Athletes subject to WADA, USADA, NCAA, or equivalent testing cannot use CJC-1295 in any form. The compound is detectable in urine through specialist anti-doping mass spectrometry protocols.

Why response varies, and where that leaves the reader

Both Paulvin and Kekic describe response to CJC-1295 as bimodal: some users notice marked changes in sleep, recovery, or perceived energy; others notice nothing. Kekic offers a framing for this from her clinical practice that maps onto Paulvin’s “how empty is your tank” observation.

“Those folks who tend to have more optimised soil, meaning internal environment, tend to respond better to those peptides than folks who have [a] variety of either preconditions, meaning they’re not diagnosed yet, or actual conditions of diseases that are diagnosed,” Kekic says. “If you have a very strong inflammatory, systemic inflammatory signal, it’s very difficult for that little small molecule like […] peptides in general to make a significant impact when your soil is disrupted.”

The Teichman 2006 trial showed what CJC-1295 can do to growth hormone and IGF-1 levels in healthy adults. It did not show what those elevations translate to in terms of body composition, recovery, sleep architecture, or any of the outcomes that the modern wellness market sells the compound for. Twenty years on, those outcome trials have not been done. The FDA’s advisory committee, asked to consider whether CJC-1295 belonged in the regulated compounding system, voted against it. Adrijana Kekic’s framing for why some people respond and some don’t (the soil matters more than the seed) is informally clinical, but it lines up with what the data actually shows: signals of effect in defined trial conditions, inconsistent translation to the heterogeneous population of real-world users.

The molecule does what its mechanism predicts. What that means for any given person remains the question CJC-1295 has not yet answered.

Photography Henry Lai